Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 2.1% – Here’s What Happened

Cel-Sci Corporation (NYSEAMERICAN:CVM) shares fell 2.1% on Wednesday. The company traded as low as $1.38 and last traded at $1.38. Approximately 27,787 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 183,912 shares. The stock had previously closed at $1.41.

Cel-Sci Stock Down 2.1%

The company has a debt-to-equity ratio of 0.35, a current ratio of 1.48 and a quick ratio of 1.42. The company has a market cap of $24.12 million, a price-to-earnings ratio of -0.14 and a beta of 0.62. The firm’s 50 day simple moving average is $1.70 and its 200-day simple moving average is $2.49.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Cel-Sci stock. Renaissance Technologies LLC raised its position in Cel-Sci Corporation (NYSEAMERICAN:CVM) by 133.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,890 shares of the company’s stock after buying an additional 20,484 shares during the quarter. Renaissance Technologies LLC owned approximately 0.42% of Cel-Sci worth $115,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About Cel-Sci

Cel-Sci Corporation is a biotechnology company focused on developing investigational immunotherapies for cancer and infectious diseases. The company’s lead product candidate, Multikine (leukocyte interleukin, injection), is designed to stimulate and coordinate the immune system’s response to cancer. It has primarily been studied as a potential treatment for locally advanced primary head and neck cancer and is not an approved commercial therapy.

Cel-Sci also develops treatments using its proprietary LEAPS (L.E.A.P.S.) technology platform, which is intended to direct immune responses against specific disease-related targets.